Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma, Inc. (Nasdaq: LUMO) is a clinical-stage biotechnology company dedicated to developing innovative therapeutics for rare diseases. Headquartered in the United States, Lumos Pharma focuses on creating treatments for conditions such as cancer and rare growth disorders. The company is active in both clinical-stage and preclinical research, emphasizing molecules that enhance the immune system's ability to fight cancer cells.
The company's portfolio includes orally administered treatments, designed to be used alongside other cancer therapies, and a promising Ebola vaccine. Recent achievements highlight the company's progress in its clinical trials, particularly the Phase 2 trials evaluating LUM-201 for moderate Pediatric Growth Hormone Deficiency (PGHD), which have shown significant results in increasing annualized height velocity (AHV). These advancements underscore Lumos Pharma's commitment to addressing unmet medical needs.
Lumos Pharma engages in strategic partnerships with pharmaceutical companies and contracts with manufacturing organizations to ensure the effective production of its treatments. A notable recent development is the appointment of Dr. Pitukcheewanont as Chief Medical Officer. Dr. Duke, with extensive experience in clinical development and medical affairs, has been integral in the advancement of Lumos Pharma's clinical programs.
Financially, Lumos Pharma is in a stable position, with cash on hand expected to support operations through Q3 2024. The company is also gearing up for a Phase 3 trial for LUM-201, poised to be a double-blinded, placebo-controlled clinical trial with a 2:1 randomization in approximately 150 patients. This trial aims to secure the approval of LUM-201 as the first oral therapeutic for moderate PGHD.
Lumos Pharma continues to exhibit its potential through its robust research initiatives, strategic partnerships, and a dedicated team of experts. The company's proactive approach in clinical and preclinical development projects positions it as a significant player in the biotechnology sector, particularly in the realm of rare diseases.
Lumos Pharma (NASDAQ:LUMO) announced the full enrollment of its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials for LUM-201, targeting Pediatric Growth Hormone Deficiency (PGHD). A total of 82 subjects are involved in the OraGrowtH210 trial, while 22 subjects are part of the OraGrowtH212 trial, which focuses on pharmacokinetic and pharmacodynamic effects. Primary outcome data is expected in Q4 2023. Interim results from the OraGrowtH210 trial showed a mean annualized height velocity of 8.6 cm/year, consistent with expectations. If LUM-201 receives FDA approval, it could be the first oral treatment for PGHD.
Lumos Pharma, Inc. (NASDAQ:LUMO) will report its full year 2022 financial results on March 1, 2023, after market close. A conference call will follow at 4:30 PM ET to discuss these results and updates on clinical and corporate activities. The company is advancing its oral therapeutic candidate, LUM-201, for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials. LUM-201 aims to provide an alternative to injections, having received Orphan Drug Designation in both the US and EU. Investors can access the conference call via a registration link or the Lumos Pharma website.
Lumos Pharma (NASDAQ:LUMO), a biopharmaceutical company, will participate in the 12th Annual LifeSci Partners Corporate Access Event in San Francisco from January 9-11, 2023. The company is advancing its oral therapeutic candidate, LUM-201, for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials. In-person one-on-one meetings with investors will be held on January 10th and 11th. LUM-201 has received Orphan Drug Designation in the US and EU, offering a new oral treatment alternative for PGHD patients.
Lumos Pharma hosted two key opinion leaders to discuss interim data from its Phase 2 trials of LUM-201 for moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD). The KOLs shared insights on the promising oral treatment option that has the potential to improve patient compliance compared to injectable therapies. Interim results indicated an annualized growth of 8.6 cm/year at 6 months, aligning with expected outcomes. The safety and tolerability of LUM-201 appear comparable to existing treatments. This novel approach could expand treatment options for patients previously deterred by injections.
Lumos Pharma (NASDAQ:LUMO) will host a KOL webinar on December 6, 2022, discussing interim data from its Phase 2 clinical trials, OraGrowtH210 and OraGrowtH212, focused on oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD). The webinar features leading experts in pediatric endocrinology, Dr. Andrew Dauber and Dr. Fernando Cassorla. LUM-201, an innovative oral therapy, received Orphan Drug Designation from the FDA and EU, promising an alternative to traditional injections for PGHD patients. A replay will be available on Lumos Pharma's website.
Lumos Pharma (NASDAQ:LUMO) announced its participation in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, in Austin, Texas. The company will host a fireside chat on November 30 at 2:00 PM (EST) and will also hold one-on-one meetings on the same day. Lumos Pharma is focused on developing LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD), currently in Phase 2 trials. The presentation can be accessed through a webcast link available on their website.
Lumos Pharma announced positive interim results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials, demonstrating a mean annualized height velocity of 8.6 cm/yr for LUM-201 at a 1.6 mg/kg/day dose. The trial is approximately 80% enrolled, with full results expected in the second half of 2023. Financially, Lumos reported a cash position of $73.7 million, estimated to sustain operations into mid-2024. R&D expenses remained stable at $4.1 million, and the net loss for Q3 2022 was $7.3 million, showing improvement from $7.5 million lost in Q3 2021.
Lumos Pharma announced that interim results for LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD), were positive in two Phase 2 trials. The OraGrowtH210 Trial, with 80% enrollment, showed a mean annualized height velocity (AHV) of 8.6 cm at six months for the 1.6 mg/kg/day dose, aligning with historical expectations of 8.3 cm. These results validate the 1.6 mg/kg/day dose for a pivotal Phase 3 trial expected in 2H 2023. No safety concerns were reported, supporting the drug's continued development.
Austin, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) - Lumos Pharma (NASDAQ: LUMO), a biopharmaceutical company, announced its participation in the upcoming Cantor Neurology & Psychiatry Conference on October 6-7. Management will engage in a panel discussion titled 'Broken circuits. Modulating the neuroendocrine systems to reestablish equipoise' on October 7 at 10:10 AM PT. Additionally, one-on-one meetings will be available on both conference days. Lumos Pharma is advancing its oral therapeutic candidate LUM-201 for Pediatric Growth Hormone Deficiency through Phase 2 clinical trials.
Lumos Pharma (NASDAQ:LUMO) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The company will present a pre-recorded session starting at 7:00 AM (EDT) on September 12. Additionally, management will hold one-on-one meetings during the event. Lumos Pharma is advancing its lead candidate, LUM-201, currently in Phase 2 trials for Pediatric Growth Hormone Deficiency (PGHD). If approved, LUM-201 would offer an oral alternative to current injection treatments.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
What does Lumos Pharma, Inc. specialize in?
What are some of the key products in Lumos Pharma's pipeline?
Where is Lumos Pharma headquartered?
What is the status of Lumos Pharma's clinical trials?
Who is the Chief Medical Officer of Lumos Pharma?
What partnerships does Lumos Pharma engage in?
What is the financial outlook for Lumos Pharma?
What is LUM-201?
Does Lumos Pharma conduct preclinical research?
How does Lumos Pharma's research contribute to cancer treatment?
